A baseline EEG biomarker (mismatch negativity amplitude) predicts whether individuals will respond to ketamine with expected or paradoxical neurological effects. This finding, confirmed across multiple datasets, establishes a measurable predictor for personalized ketamine response, with direct applications to treatment stratification and clinical trial design.
Key Points
- Higher baseline mismatch negativity predicts expected ketamine reduction response
- Lower baseline mismatch negativity predicts paradoxical increase in ketamine response
- Biomarker validated across three pharmaceutical-sponsored studies with statistical significance
Longevity Analysis
Individual variation in neurological response to pharmacological interventions remains a primary barrier to effective treatment. This work demonstrates how a simple, objective biomarker can decode the direction and magnitude of response before treatment begins—shifting clinical strategy from trial-and-error to prediction. For aging populations where ketamine-assisted interventions are increasingly studied for depression and cognitive decline, pre-treatment stratification based on neurophysiological state reduces adverse events, optimizes dosing, and accelerates identification of responders. The disordinal effect itself—where lower baseline signal predicts paradoxical response—illustrates why population averages obscure individual biology; understanding personal neurophysiological architecture becomes the foundation for any intervention.
Original published by LT Wire.